ESTABLISHING OUTCOMES FOR THE BALTIMORE LONGITUDINAL STUDY OF AGING COHORT. THE

确定巴尔的摩老龄化队列纵向研究的结果。

• 批准号: 7940094
• 负责人: KATE TORRES
• 金额: $ 63.82万
• 依托单位: WESTAT, INC.
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-08-15 至 2012-08-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7940094
• 关键词: ESTABLISHING; OUTCOMES; BALTIMORE; LONGITUDINAL; STUDY

To perform home-based visits in the BLSA participants who, for different reasons, cannot come to the study clinic in Baltimore for a traditional follow-up evaluation. Initially, these visits will include 481 BLSA participants who are currently inactive but never officially dropped out of the study. It is expected that an average of 150 participants will become eligible for the home visit program for each of the 5 years of follow-up, except for the first year when it is expected to have 125 eligible participants. Home visits shall be performed following the schedule specified for regular BLSA visits to the study clinic (every 4 years for participants less than 60 years old, every two years for 60-79 and annually for 80 and older). The main objectives are to: perform follow-up evaluations of BLSA participants who cannot come to Baltimore for a traditional assessment in the study dinic; create outcome measures that maximize the scientific use of the extensive data previously collected in these participants; increase the value of the study by reducing the biasing effect of "informative censoring"; expand the collection of biological samples in participants who have developed substantial comorbidity and disability; obtain informed consent from participants for the use of biological samples that they previously donated to the study to address new research questions.

对因不同原因不能来巴尔的摩学习诊所进行传统后续评估的BLSA参与者进行基于家庭的访问。最初，这些访问将包括481名目前不活跃但从未正式退出研究的BLSA参与者。预计在5年的后续行动中，平均每年将有150名参与者有资格参加家访方案，但第一年预计将有125名合格参与者。家访应遵循BLSA定期访问研究诊所的规定时间表(60岁以下的参与者每4年访问一次，60-79岁的参与者每两年访问一次，80岁及以上的参与者每年访问一次)。主要目标是：对不能来巴尔的摩进行传统评估的BLSA参与者进行后续评估；制定成果措施，最大限度地科学利用以前在这些参与者中收集的大量数据；通过减少“信息性审查”的偏颇效应增加研究的价值；扩大对患有严重合并症和残疾的参与者的生物样本的收集；征得参与者的知情同意，允许他们使用以前捐赠给研究的生物样本，以解决新的研究问题。